AstraZeneca to pay $425 million to end US lawsuits over heartburn drugs
Reuters
Published Oct 03, 2023 02:15AM ET
Updated Oct 03, 2023 04:51PM ET
By Brendan Pierson
(Reuters) -Britain's AstraZeneca (NASDAQ:AZN) has agreed to pay $425 million to settle about 11,000 lawsuits in the United States that claimed its heartburn drugs Nexium and Prilosec caused chronic kidney disease.
AstraZeneca did not admit wrongdoing under the settlement, part of broader litigation against makers of a class of heartburn drugs called proton pump inhibitors (PPIs). Its shares dipped 0.4%.
"Today's settlements are a significant victory for the thousands of patients who suffered kidney injuries as a result of using" the drugs, the plaintiffs' attorney Chris Seeger said in a statement.
A single lawsuit is still scheduled to go to trial in April in Louisiana, according to AstraZeneca.
Nexium brought AstraZeneca about $1.3 billion in revenue last year. The company did not report sales figures for Prilosec.
Many lawsuits against makers of PPIs were consolidated in a New Jersey federal court in 2017, while other cases covered by the settlement are in New Jersey and Delaware state courts.
Plaintiffs in the lawsuits allege that PPI use led to kidney damage or failure, and that the companies failed to warn of the risk. The lawsuits include claims over both the prescription versions of the drugs and the lower-dose over-the-counter versions.
Claims remain pending against Abbott Laboratories (NYSE:ABT) and Takeda Pharmaceutical over their PPI Prevacid, and against Takeda over its Dexilant drug.
Separate litigation is pending against GSK and other companies over the now-withdrawn heartburn drug Zantac, which plaintiffs say can cause cancer. The company has settled individual cases before trial, but still faces tens of thousands in state courts.
GSK and other companies that have sold Zantac previously won dismissal of some 50,000 cases that were pending in federal court after a judge concluded the claims were not based on sound science.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.